Glucose Counterregulation in Long Standing Type 1 Diabetes

NACompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

May 31, 2016

Study Completion Date

March 5, 2021

Conditions
Hypoglycemia UnawarenessType 1 DiabetesHealthy
Interventions
DEVICE

RT-CGM

Each device is approximately the size of a pager and transmits with a subcutaneously placed sensor consisting of a 21 - 26 gauge needle 5 - 12 mm in length. Sensors are placed using sterile precautions and changed every 3 - 7 days depending on the manufacturers' instructions. All devices are approved as adjunctive tools to blood glucose monitoring that will be continued at least 4 times daily, before each meal and at bedtime.

Trial Locations (3)

19104

Clinical and Translational Research Center, Hospital of University of Pennsylvania, Philadelphia

Rodebaugh Diabetes Center, University of Pennsylvania, Philadelphia

University of Pennsylvania - Institute for Diabetes, Obesity and Metabolism, Philadelphia

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

University of Pennsylvania

OTHER

NCT01474889 - Glucose Counterregulation in Long Standing Type 1 Diabetes | Biotech Hunter | Biotech Hunter